Moxidectin
An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.
Berat Molekul
639,8000 g/mol
LogP
4,30
TPSA
116,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C
InChI
InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
Molecular Formula
C37H53NO8
HBD / HBA
2 / 9
Ikatan yang Dapat Dirotasi
3
Atom Berat
46
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Yes, Moxidectin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2104415. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9832912. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="moxidectin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/moxidectin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/moxidectin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/moxidectin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="moxidectin"></drugfyi-drug>